DMTTF News and Press, Small Pharma From 10/02/23

LONDON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Mr. Peter Rands disposed of an aggregate of 1,532,001 common shares in the capital of Small Pharma Inc. (the “ Company ”) between September 25, 2023 and September 27, 2023 at an average price of $0.177 per common share for aggregate proc...

2023-09-29 10:00:00 ET More on psychedelic drugs Atai Life Sciences: RL-007, Targeting Schizophrenia Subpopulation With No FDA Approved Therapies With ecstasy a potential PTSD therapy, psychedelic treatments could take off Psychedelic Stocks = Super-Risky Biote...

• Results suggest that SSRIs enhance the efficacy of SPL026 (DMT) when administered to MDD patients on a stable dose of SSRIs versus patients not on SSRIs • At Week 4, 100% of patients in the SSRI cohort responded to SPL026 (DMT) with 92% of patients in remission from depres...

2023-08-28 11:18:10 ET More on Cybin, Small Pharma Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets. Psychedelic Stocks: Don't Bet On Just 1 Company Cybin renews $35M ATM equity offering Cybin stock falls on pricing discounted stock and ...

- All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics - - Two proprietary, advanced clinical programs in development for depression and anxiety disorders with demonstrated safety and efficacy - - Combined portfolio creates the indust...

• Last patient dosed in SPL026-SSRI drug interaction study with data readout anticipated in Q3 2023 • Potential for an expedited route to an international, multi-site Phase II study with SPL028 in 2024, based on clinical findings across SPL026 and SPL028 programs to date ...

2023-07-05 07:34:29 ET Biotechnology company Small Pharma ( TSXV: DMT:CA ) ( OTCQB:DMTTF ) said on Wednesday that Peter Rands, co-founder, chief innovation and intellectual property officer and former CEO, has left his executive positions and directorship, effective July ...

• Preliminary findings from ongoing Phase I trial of second-generation DMT asset SPL028 indicate the potential for a unique therapeutic profile • Proof-of-concept data from Company’s native DMT program, SPL026, offers potential for an expedited rou...

LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that Mr. P...

LONDON, May 25, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces an update...